SCHEMBL6970787

SCHEMBL6970787

O=C1C2CCC1CC(Cc1ccc(Cl)cc1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
MAOB P27338 3/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.38
FPR2 P25090 3/20 0.36
PROKR1 Q8TCW9 3/20 0.36
TSHR P16473 2/20 0.36
GRIN1 Q05586 2/20 0.36
GMNN O75496 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
MTOR P42345 1/20 0.36
BLM P54132 1/20 0.36
GRIN2B Q13224 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SLC6A3 Q01959 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119467 0.76 ALDH1A1 (0.59) ALDH1A1MEN1KMT2ALMNAFPR2
SCHEMBL6785682 0.74 ALDH1A1 (0.50) ALDH1A1MAOBMEN1KMT2ALMNA
SCHEMBL6942011 0.73 KCNH2 (0.51) ALDH1A1FPR2PROKR1SLC6A3
SCHEMBL27487290 0.71 ALDH1A1 (0.44) ALDH1A1MAOBMEN1KMT2ALMNA
SCHEMBL25838949 0.71 ALDH1A1 (0.54) ALDH1A1LMNACYP3A4SLC6A3
Formic Acid SCHEMBL27995138 0.70 ALDH1A1 (0.40) ALDH1A1MAOBMEN1KMT2ALMNA
SCHEMBL11791432 0.69 POLB (0.46) ALDH1A1MAOBLMNATSHRCYP3A4
SCHEMBL6979816 0.69 TSHR (0.38) ALDH1A1MAOBLMNATSHR
SCHEMBL3130172 0.68 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AFPR2PROKR1
SCHEMBL894700 0.68 GBA1 (0.66) ALDH1A1FPR2PROKR1TSHRGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244639-A4 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-02-05 EP disclosed
US-6495561-B2 TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE MERCK & CO., INC. 2002-12-17 US disclosed
EP-1244639-A1 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 EP disclosed
US-20020055519-A1 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists MERCK SHARP & DOHME CORP. 2002-05-09 US disclosed
US-6380205-B1 QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN MERCK & CO., INC. 2002-04-30 US disclosed
US-20020032207-A1 2-Cyclohexyl quinazoline NMDA/NR2B antagonists MERCK & CO., INC. 2002-03-14 US disclosed
US-6291499-B1 TREATING MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE MERCK & CO., INC. 2001-09-18 US disclosed
WO-2001032634-A1 2-CYCLOHEXYL BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055519-A1 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists GRIN2C, GRIN1, GRIN3A ALDH1A1 2175/4885MAOB 4021/4885MEN1 4512/4885
US-20020032207-A1 2-Cyclohexyl quinazoline NMDA/NR2B antagonists GRIN2C, GRIN1, GRIN3A ALDH1A1 2927/4885MAOB 3778/4885MEN1 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.